Sun. Jul 21st, 2019

Nightstar Therapeutics along with Genocea Biosciences is a critical Contrast

Genocea Biosciences Logo

Nightstar Therapeutics and Genocea Biosciences are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

39.4% of Nightstar Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Genocea Biosciences shares are held by institutional investors. 2.3% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Genocea Biosciences has higher revenue and earnings than Nightstar Therapeutics. Nightstar Therapeutics is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

 

Risk & Volatility

Nightstar Therapeutics has a beta of 3.25, suggesting that its share price is 225% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 3.04, suggesting that its share price is 204% more volatile than the S&P 500.

Nightstar Therapeutics presently has a consensus price target of $28.37, suggesting a potential upside of 11.25%. Genocea Biosciences has a consensus price target of $5.75, suggesting a potential upside of 717.92%. Given Genocea Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Genocea Biosciences is more favorable than Nightstar Therapeutics.

Large investors have recently modified their holdings of the stock. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. purchased a new position in Nightstar Therapeutics in the 4th quarter worth $127,000. JPMorgan Chase & Co. purchased a new position in shares of Nightstar Therapeutics in the third quarter valued at about $214,000. Virtus ETF Advisers LLC purchased a new position in shares of Nightstar Therapeutics in the fourth quarter valued at about $314,000. Squarepoint Ops LLC boosted its stake in shares of Nightstar Therapeutics by 106.7% during the 4th quarter. Squarepoint Ops LLC now owns 43,886 shares of the company’s stock valued at $506,000 after purchasing an additional 22,651 shares in the last quarter. Finally, Harvest Management LLC bought a new stake in shares of Nightstar Therapeutics during the 1st quarter valued at about $685,000. Institutional investors own 39.35% of the company’s stock.